Bayer's Two Bulls: Same Rating, a EUR 13.50 Gap, and One Margin Number That Settles It
Published on 11/20/2026 at 07:52 | Editorial boerse-global.deBayer shares slipped 2.3% to EUR 54.48 on Thursday as a weak German equity market weighed on the stock — yet the day's real story sits in two analyst notes that point in opposite directions while carrying the same verdict.
Jefferies' Michael Leuchten kept Bayer at "Hold" with a EUR 48.50 target after his firm's own pharma conference in London, citing firmer evidence of growth in the company's drug business. A day earlier, Berenberg's Sebastian Bray had raised his target from EUR 53.50 to EUR 62.00 — also at "Hold." Measured against Thursday's close, one number implies upside and the other implies decline. A shared rating, in other words, tells investors almost nothing about what the stock is actually worth.
The split has a rationale
Bray's case rests partly on a corporate action rather than the drug portfolio itself: he flagged a possible initial public offering of Monsanto before the end of the decade, with proceeds from such a listing potentially channeled into Bayer's pharmaceutical development. That is a financing argument, not an earnings one — and it helps explain why Berenberg's target sits well above Jefferies'.
Bayer's own guidance is the arbiter
The company gave both camps something to work with in its third-quarter 2026 report, lifting its outlook for the pharma margin alongside group-level guidance for EBITDA before special items and free cash flow. Quarterly revenue came in at EUR 10.053 billion, with EBITDA before special items of EUR 1.615 billion.
Should investors sell immediately? Or is it worth buying Bayer?
Whether those upgraded expectations translate into reported profit is the question that separates the two targets. A raised forecast is not proof of higher profitability — and that distinction is where the bull and bear cases diverge.
Asundexian adds a sales lever, not yet a margin
Bayer has also disclosed US approval for Asundexian to reduce the risk of recurrent stroke, opening an additional revenue avenue. What matters for the margin debate is whether that approval produces an actual earnings contribution; the clearance on its own says nothing about that.
What the next print must show
If Bayer confirms the higher pharma margin and it flows through to group earnings, the scenario underpinning the EUR 62.00 target gains operational substance. Should the pharma margin miss the upgraded bar, the question shifts to whether the improved group earnings outlook can hold at all — and the lower target carries more weight.
Bayer at a turning point? This analysis reveals what investors need to know now.
The next set of results is the concrete test. Confirm the profitability improvement in pharmaceuticals, and the focus moves to its contribution to group earnings. Disappoint on the margin first, and the more optimistic case loses its central operational support.
Ad
Bayer Stock: New Analysis - 20 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
